Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

联系方式

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

市值

$135.27M

市盈率 (TTM)

-1.2

18.2

股息率

52周最高

$55.89

52周最低

$5.20

52周范围

18%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基于 8 年期基本面

疲弱 • 2.2 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2018-2025

财务仪表盘

Q4 2025 数据

营业收入

$1.29M+0.00%

近4季度走势

每股收益

-$5.33+0.00%

近4季度走势

自由现金流

-$17.79M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Collaboration Revenue Increased Collaboration revenue reached $6.4M USD in 2025, up $4.1M USD from $2.3M USD in 2024, driven by Novo Nordisk agreement.

KRRO-121 Advancement Progressing Lead candidate KRRO-121 targets hyperammonemia with regulatory filing anticipated in the second half of 2026 for first-in-human trial.

AATD Candidate Nomination Nearing Next-generation AATD program expects development candidate nomination in the second quarter of 2026 following pivot to GalNAc delivery.

Cash Runway Extended Cash runway extends into the second half of 2028 supporting key milestones after recent financing activities and restructuring efforts.

关注风险

Continued Operating Losses Expected Net loss widened to $(117.3M) USD in 2025 from $(83.6M) USD in 2024; expects increasing expenses and negative cash flow indefinitely.

Significant Asset Impairment Recognized $30.9M USD non-cash impairment charge in Q4 2025 related to operating lease and fixed assets following program termination.

Pipeline Concentration Risk High Business heavily reliant on KRRO-121 success; only nominated candidate after terminating KRRO-110 program due to insufficient functional protein levels.

Novel Technology Unproven RNA editing technology is new with limited clinical validation; preclinical success does not guarantee positive results in human trials.

前瞻展望

Advance KRRO-121 Clinical Trial Anticipate regulatory filing for KRRO-121 in H2 2026 to commence first-in-human trial for hyperammonemia treatment indications.

Optimize OPERA Platform Further Continue enhancing OPERA platform using computational models and new data to expedite design and optimization of future lead candidates.

Advance ALS and Longevity Programs Continue advancing ALS program targeting TDP-43 aggregation and longevity program targeting AMPKγ1 activation through preclinical studies.

Seek Strategic Partnerships Plan to actively seek innovative collaborations and strategic alliances to maximize OPERA platform potential across rare and prevalent diseases.

同行对比

营业收入 (TTM)

AMRN

$183.87M

-19.6%

ADCT

$81.36M

+14.9%

AUTL

$75.35M

+644.6%

毛利率 (最新季度)

AMRN

119.2%

+7.3pp

ALT

100.0%

-299200.0pp

ADCT

84.5%

-2.7pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$782.15M	-4.9	-101.3%	9.4%
ADCT	$543.75M	-4.5	66.2%	135.9%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-20.3%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月5日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据